Terms: = Small Cell Lung Cancer AND ERBB2, c-erb B2, 2064, P04626, ENSG00000141736, c-erbB2, HER-2/neu, HER2, TKR1, NEU, NGL, HER-2 AND Prognosis
203 results:
1. Landscape of Concomitant Driver Alterations in Classical
Wang H; Lin L; Liang C; Pang J; Yin JC; Zhang J; Shao Y; Sun C; Guo R
JCO Precis Oncol; 2024 Aug; 8():e2300520. PubMed ID: 39102631
[TBL] [Abstract] [Full Text] [Related]
2. Ultrasonic-responsive piezoelectric stimulation enhances sonodynamic therapy for her2-positive breast cancer.
Chen Z; Yang L; Yang Z; Wang Z; He W; Zhang W
J Nanobiotechnology; 2024 Jun; 22(1):369. PubMed ID: 38918812
[TBL] [Abstract] [Full Text] [Related]
3. Antibody-Drug Conjugates as Novel Therapeutic Agents for Non-small cell lung Carcinoma with or without Alterations in Oncogenic Drivers.
Somme LB; Chouaid C; Moinard-Butot F; Barbe-Richaud JB; Greillier L; Schott R
BioDrugs; 2024 Jul; 38(4):487-497. PubMed ID: 38767823
[TBL] [Abstract] [Full Text] [Related]
4. [Effect of peripheral blood inflammatory indicators on the efficacy of immunotherapy in patients with advanced non-small cell lung cancer and chronic obstructive pulmonary disease].
Bi ZK; Xu Y; Guo L; Zhang WJ; You YT; Li JW; Zhao CL; Shan YF; Xia TT; Li YF; Xu Z; Fan Y; Bai L
Zhonghua Yi Xue Za Zhi; 2024 May; 104(18):1601-1609. PubMed ID: 38742347
[No Abstract] [Full Text] [Related]
5. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
[TBL] [Abstract] [Full Text] [Related]
6. Targeted therapeutic options in early and metastatic NSCLC-overview.
Gálffy G; Morócz É; Korompay R; Hécz R; Bujdosó R; Puskás R; Lovas T; Gáspár E; Yahya K; Király P; Lohinai Z
Pathol Oncol Res; 2024; 30():1611715. PubMed ID: 38605928
[TBL] [Abstract] [Full Text] [Related]
7. Factors influencing blood tumor marker concentrations in the absence of neoplasia.
Trapé J; Fernández-Galán E; Auge JM; Carbonell-Prat M; Filella X; Miró-Cañís S; González-Fernández C;
Tumour Biol; 2024; 46(s1):S35-S63. PubMed ID: 38517826
[TBL] [Abstract] [Full Text] [Related]
8. miRNA-449c-5p regulates the JAK-STAT pathway in inhibiting cell proliferation and invasion in human breast cancer cells by targeting erbb2.
Li L; Zhang Y; Yang K; Liu W; Zhou Z; Xu Y
Cancer Rep (Hoboken); 2024 Feb; 7(2):e1974. PubMed ID: 38351535
[TBL] [Abstract] [Full Text] [Related]
9. Recurrence/prognosis estimation using a molecularly positive surgical margin-based model calls for alternative curative strategies in pIIIA/N2 NSCLC.
Li L; He K; Zhou T; Xu Y; Pang J; Yu Q; Gao Y; Shi H; Zhu H; Li M; Yu J; Yuan S
Mol Oncol; 2024 Jun; 18(6):1649-1664. PubMed ID: 38327028
[TBL] [Abstract] [Full Text] [Related]
10. Deciphering the heterogeneity of neutrophil cells within circulation and the lung cancer microenvironment pre- and post-operation.
Liu F; Liu X; Liu Y; Chen D; Liu X; Qin C; Song Y; Fang H; Wu D
Cell Biol Toxicol; 2024 Feb; 40(1):11. PubMed ID: 38319415
[TBL] [Abstract] [Full Text] [Related]
11. Upfront Multiplex Gene Test Helps Prolong Survival in Advanced Non-small cell lung cancer.
Kanasaki H; Ozawa Y; Nakamura N; Nagasaki K; Matsuyama W; Akahori D; Niwa M; Ogasawara T; Sato J
Anticancer Res; 2024 Feb; 44(2):723-730. PubMed ID: 38307579
[TBL] [Abstract] [Full Text] [Related]
12. Tumor therapy by targeting extracellular hydroxyapatite using novel drugs: A paradigm shift.
Tantawy MN; McIntyre JO; Yull F; Calcutt MW; Koktysh DS; Wilson AJ; Zu Z; Nyman J; Rhoades J; Peterson TE; Colvin D; McCawley LJ; Rook JM; Fingleton B; Crispens MA; Alvarez RD; Gore JC
Cancer Med; 2024 Feb; 13(3):e6812. PubMed ID: 38239047
[TBL] [Abstract] [Full Text] [Related]
13. Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC; Newman S; Li A; Joy M; Lyons M; Pham MP; Lucas P; Smith K; Sander C; Isett B; Davar D; Najjar YG; Zarour HM; Kirkwood JM; Luke JJ; Bao R
J Immunother Cancer; 2023 Oct; 11(10):. PubMed ID: 37857525
[TBL] [Abstract] [Full Text] [Related]
14. Real-World Clinical Outcomes for Patients with
Li K; Bosdet I; Yip S; Ho C; Laskin J; Melosky B; Wang Y; Sun S
Curr Oncol; 2023 Jul; 30(8):7099-7111. PubMed ID: 37622996
[TBL] [Abstract] [Full Text] [Related]
15. Trastuzumab deruxtecan (DS8201) for advanced non-small cell lung cancer with her2 exon 20 insertion mutation: a case report.
He X; Hou L; Bai J; Sun C; Wang D; An G
Anticancer Drugs; 2024 Jan; 35(1):101-108. PubMed ID: 37615532
[TBL] [Abstract] [Full Text] [Related]
16. Eosinophil and IFN-γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy.
Hu WT; Zhang Q; Zhang Z; He X; Zhou M; Guo Y; Wang X
Front Immunol; 2023; 14():1112409. PubMed ID: 36949952
[TBL] [Abstract] [Full Text] [Related]
17. [Clinicopathological features of patients with RET fusion-positive non-small cell lung cancer].
Tan Q; Ji Y; Wang XL; Wang ZW; Qi XW; Liu YK
Zhonghua Bing Li Xue Za Zhi; 2023 Feb; 52(2):124-128. PubMed ID: 36748131
[No Abstract] [Full Text] [Related]
18. The expression of her2/neu in patients with lung cancer and its associated factors.
Lashkarizadeh M; Lashkarizadeh M; Nikian M; Kouhestani Parizi M
Clin Respir J; 2023 Feb; 17(2):90-95. PubMed ID: 36617420
[TBL] [Abstract] [Full Text] [Related]
19. Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.
Medikonda R; Pant A; Lim M
Adv Exp Med Biol; 2023; 1394():73-84. PubMed ID: 36587382
[TBL] [Abstract] [Full Text] [Related]
20. Transcriptomic FHIT
Brisebarre A; Ancel J; Ponchel T; Loeffler E; Germain A; Dalstein V; Dormoy V; Durlach A; Delepine G; Deslée G; Polette M; Nawrocki-Raby B
Front Immunol; 2022; 13():1058531. PubMed ID: 36544755
[TBL] [Abstract] [Full Text] [Related]
[Next]
